Randall B. Smith

发表

An evaluation of population pharmacokinetics in therapeutic trials. Part III. Prospective data collection versus retrospective data assembly

R B Smith, T H Grasela, E J Antal, 1989, Clinical pharmacology and therapeutics.

Alprazolam in End‐Stage Renal Disease: I. Pharmacokinetics

P. Kroboth, B. Piraino, V. Schmith, 1991, Journal of clinical pharmacology.

The Influence of Obesity on the Pharmacokinetics of Oral Alprazolam and Triazolam

D. Greenblatt, R. Shader, D. Abernethy, 1984, Clinical pharmacokinetics.

Pharmacodynamic evaluation of the benzodiazepine–oral contraceptive interaction

P. Kroboth, G. Stoehr, R. Juhl, 1985, Clinical pharmacology and therapeutics.

Compartmental Model Analysis in Pharmacokinetics

Randall B. Smith, Joseph C. Fleishaker, J. C. Fleishaker, 1987, Journal of clinical pharmacology.

The Relationship of Alprazolam Dose to Steady‐State Plasma Concentrations

D. Ciraulo, D. Greenblatt, R. Shader, 1990, Journal of clinical psychopharmacology.

An evaluation of population pharmacokinetics in therapeutic trials. Part II. Detection of a drug‐drug interaction

R B Smith, T H Grasela, E J Antal, 1987, Clinical pharmacology and therapeutics.

Pharmacodynamic Modelling

R B Smith, P. Kroboth, V D Schmith, 1991, Clinical pharmacokinetics.

Alprazolam in the elderly: pharmacokinetics and pharmacodynamics during multiple dosing

P. Kroboth, J. McAuley, Randall B. Smith, 2005, Psychopharmacology.

Temporal Variation in Triazolam Pharmacokinetics and Pharmacodynamics After Oral Administration

P. Kroboth, J. P. Phillips, R. Smith, 1986, Journal of clinical pharmacology.

Effects of end‐stage renal disease and aluminum hydroxide on temazepam kinetics

P. Kroboth, J. Puschett, R. Rault, 1985, Clinical pharmacology and therapeutics.

Pharmacokinetics and Clinical Effects of Alprazolam Following Single and Multiple Oral Doses in Patients With Panic Disorder

D. Ciraulo, D. Greenblatt, H. Boxenbaum, 1986, Journal of clinical pharmacology.

Comparing probabilistic and descriptive analyses of time-dose-toxicity relationship for determining no-observed-adverse-effect level in drug development.

A. Berges, Chao Chen, E. Hénin, 2015, Toxicology and applied pharmacology.

Pharmacokinetic considerations in exchange transfusion in neonates

R. Leff, G. Yakatan, J. Kay, 1978, Clinical pharmacology and therapeutics.

Lack of Effect of Erythromycin and Ketoconazole on the Pharmacokinetics and Pharmacodynamics of Steady‐State Intranasal Levocabastine

Honghui Zhou, S. Travers, B. Wiesinger, 1999, Journal of clinical pharmacology.

Triazolam protein binding and correlation with alpha‐1 acid glycoprotein concentration

P. Kroboth, R. Rault, Randall B. Smith, 1984 .

Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients.

D. Jung, J. Hulse, A. Dorr, 1995, Clinical therapeutics.

Triazolam pharmacokinetics after intravenous, oral, and sublingual administration.

P. Kroboth, R. Bertz, F. Kroboth, 1995, Journal of clinical psychopharmacology.

Pharmacodynamics of Triazolam After Intravenous Administration

P. Kroboth, P. D. Varner, R. Smith, 1987, Journal of clinical pharmacology.

Phenytoin-dexamethasone interaction: a previously unreported observation.

A. Young, R. Blouin, R. Rapp, 1981, Surgical neurology.

Alprazolam in end‐stage renal disease. II. Pharmacodynamics

P. Kroboth, B. Piraino, V. Schmith, 1992, Clinical pharmacology and therapeutics.